Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
نویسندگان
چکیده
منابع مشابه
Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control
E ven with current guidelines, treatment algorithms, and recommendations available regarding diabetes management (1,2), providers struggle with adding therapies to manage postprandial hyper-glycemia after basal insulin therapy in combination with oral antidia-betic medications (OADs) has failed to control a patient's hyperglycemia. Historically, after titration of basal insulin to achieve morni...
متن کاملBasal Insulin Use With GLP-1 Receptor Agonists
IN BRIEF The combination of basal insulin and a glucagon-like peptide 1 receptor agonist is becoming increasingly common and offers several potential benefits to patients with type 2 diabetes. Clinical studies have demonstrated improved glycemic control and low risks of hypoglycemia and weight gain with the combination, which provides a safe and effective alternative to basal-bolus insulin with...
متن کاملCase Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy
Current treatment of type 2 diabetes begins with diet and lifestyle modifications accompanied by use of oral antihyperglycemic medications. Despite multiple therapeutic options for people with type 2 diabetes, the disorder continues to progress, resulting in the gradual deterioration of glycemic control over time (1). This is the result of insulin resistance and progressive decline in β-cell fu...
متن کاملCombination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
Treatment algorithms for type 2 diabetes call for intensification of therapy over time as the disease progresses and glycaemic control worsens. If diet, exercise and oral antihyperglycaemic medications (OAMs) fail to maintain glycaemic control then basal insulin is added and ultimately prandial insulin may be required. However, such an intensification strategy carries risk of increased hypoglyc...
متن کاملCombination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
Glycemic control has been considered a major therapeutic goal within the scope of diabetes management, as supported by robust observational and experimental evidence. However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Clinical Diabetes
سال: 2015
ISSN: 0891-8929,1945-4953
DOI: 10.2337/diaclin.33.2.73